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Abstract
We describe a bioinformatic tool, Tumor Aberration Prediction Suite (TAPS), for the identification of allele-specific
copy numbers in tumor samples using data from Affymetrix SNP arrays. It includes detailed visualization of
genomic segment characteristics and iterative pattern recognition for copy number identification, and does not
require patient-matched normal samples. TAPS can be used to identify chromosomal aberrations with high
sensitivity even when the proportion of tumor cells is as low as 30%. Analysis of cancer samples indicates that
TAPS is well suited to investigate samples with aneuploidy and tumor heterogeneity, which is commonly found in
many types of solid tumors.
Background
A characteristic feature of cancer cells is that their geno-
mic DNA is altered [1]. Tumor cells frequently contain
a wide range of aberrations, with gains, losses and trans-
locations of genetic material often affecting a majority of
the genome. In cancer, genomic aberrations are acquired
during a process of tumor evolution, selecting for a
tumor genome that provides growth and survival advan-
tages over other cells.
T h eS N Pa r r a yi sc u r r e n t l yo n eo ft h em o s te f f i c i e n t
technologies for detecting copy number aberrations in
tumor cells. SNP arrays measure allele-specific signals
from SNP probes (A and B), allowing detection of both
copy number alterations and allelic imbalances. High-
density SNP arrays are available primarily on Affymetrix
and Illumina platforms. Both platforms were originally
developed for genotyping of diploid genomes. In order
to use them for copy number analysis of tumor gen-
omes, specialized bioinformatic tools are required. The
main aim of such tools is the identification of bound-
aries and copy number for every aberration.
A commonly used strategy for identification of regions
affected by genomic aberrations is segmentation of the
total probe signals into genomic regions with similar
average signal [2]. Conventional tools for copy number
analysis only consider the total probe intensities relative
to the average intensity of a set of (diploid) reference
samples, usually called the Log-ratio [3]. Segments with
an average Log-ratio near zero are often assumed to be
copy number two, and any deviation beyond certain
thresholds is called loss or gain accordingly.
The allele-specific copy number - that is, the total
copy number and the specific number of copies of each
original sister chromosome - can be determined from
the allele-specific signals of the SNP markers. Several
methods detect relative differences in total signals and
allele-specific signal without determining absolute copy
number [4,5]. One tool provides a manual interpretation
of Affymetrix 500 K SNP array data, illustrated on glio-
blastomas [6]. An automated method for data from the
Illumina platform has also been proposed [7]. PICNIC
(Predicting Integral Copy Number in Cancer) can iden-
tify allele-specific copy numbers in cell lines and very
pure tumor samples and is designed for Affymetrix SNP
6.0 arrays [8]. However, tumor samples frequently suffer
from an admixture of genetically normal cells. The
effects of normal cell content on probe and SNP
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when analyzing most tumor samples. Göransson et al.
[5] proposed the CNNLOH Quantifier to estimate the
proportion of normal cells and copy-number-neutral
loss of heterozygosity (LOH) from allele frequency. GAP
(Genome Alteration Print), OncoSNP and ASCAT
(Allele-Specific Copy number Analysis of Tumors) have
been developed for allele-specific copy number analysis
of Illumina SNP array data [9-11]. TumorBoost allele-
specific signal normalization is suitable for Affymetrix
SNP arrays with paired normal samples [12]. Methods
developed for Illumina SNP arrays are not directly
applicable to data from Affymetrix arrays due to differ-
ent signal and noise characteristics. PSCN (Parent-Speci-
fic Copy Number) has recently been published as a
platform-independent solution and was shown to out-
perform several frequently used copy number analysis
tools on a dilution data set based on a diploid tumor
sample [13].
Tumor ploidy
It is well known that many types of tumors frequently
have genomic aberrations involving gain or loss of
whole or large parts of chromosomes. Thus, the average
ploidy or total genomic content of tumor cells cannot
be assumed to be 2N. A fixed amount of genomic DNA
is hybridized to the array (rather than a fixed number of
cells), and the basic normalization procedure includes
median-centering of the total probe intensities. Conven-
tional microarray copy number analysis is based on
comparing the probe intensities to those of a set of
diploid reference samples. This works well for detecting
aberrations in diploid non-cancer samples as the nor-
malized intensity of copy number two should coincide
for query and reference data. It may also work reason-
ably well on tumors that have few and relatively small
genomic aberrations. However, many individual tumors
have such extensive genomic aberrations that the
assumption that the query cells have a genomic content
of 2N on average is severely violated. This can lead to
systematic misidentification of copy numbers through-
out the entire sample, by one or more copies [8].
Tumor heterogeneity
Tumor samples are a mix of cancer cells and genetically
normal cells. The proportion of tumor cells can vary
considerably, complicating the analysis since the mea-
sured signal from any locus will be a combined signal
from both tumor and non-tumor cells. If the proportion
of tumor cells is too low, aberrations will remain unde-
tected. Comparisons of detected aberrations in crude
tumor samples with those detected in microdissected
tumor cells from the same original samples have shown
that many copy number aberrations are overlooked even
in relatively pure tumor samples [5].
Tumor cell heterogeneity
Some copy number alterations are variable in nature, their
genomic content prone to repeated duplication or deletion
in future cell generations [14]. In addition, copy number
aberrations in tumor cells may arise several times through-
out tumor development, and may give rise to different
subclones. New aberrations may change the proliferative
activity of that cell and its progeny, possibly making them
constitute a growing proportion and eventually a majority
of the tumor cells. The extent of the proliferative advan-
tage and the time between occurrence of the aberration
and tumor collection influence the proportion of tumor
cells with each aberration [15]. As a consequence of the
tumor cell heterogeneity, the average copy numbers of
heterogenic genomic regions may be non-integer. Long
non-integer regions may severely disturb a model-based
copy number analysis as they do not fit the pre-deter-
mined relationship between signal and copy number.
Tumor Aberration Prediction Suite
We present a tool and algorithm for allele-specific copy
number analysis of tumor samples on Affymetrix 500 K
and SNP 6.0 arrays called Tumor Aberration Prediction
Suite (TAPS). It handles samples with aneuploidy and
the presence of normal cells and facilitates detection of
tumor cell heterogeneity. We describe allele-specific
copy number profiling of 7 lung cancer cell lines and 12
colon tumor samples, partially validated through spectral
karyotyping (SKY) and DNA ploidy analysis.
Results and discussion
We developed TAPS as a tool for investigation and
identification of allele-specific copy numbers from Affy-
metrix SNP array data. TAPS handles samples with
aneuploidy and significant normal cell content, and
facilitates detection of several kinds of tumor cell het-
erogeneity. Raw array data are first normalized and seg-
mented by conventional means (see Materials and
methods). TAPS visualizes and estimates allele-specific
copy number of the genomic segments based on their
average probe intensity (Log-ratio) and their allelic
imbalance ratio (see Materials and methods). The allelic
imbalance ratio is sensitive to signal differences in het-
erozygous SNPs in a genomic region, and is robust
enough to distinguish different allele-specific copy num-
ber variants based on small changes in allele-specific sig-
n a l s( F i g u r e1 b ) .I ti sp a r t i c u l a r l yu s e f u la si td o e sn o t
require heterozygous (informative) SNPs to be known in
advance or to be estimated through an allele frequency
cutoff. TAPS is available from the authors [16].
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Page 2 of 10All aberrations in a single sample are visualized by
plotting the allelic imbalance ratio against the average
Log-ratio for the genomic segments. Segments group
into clusters where the relative positions of the clusters
provide the basis for manual or automatic allele-specific
copy number calls (Figure 1c). Highlighting separate
chromosomes or arbitrary segments in this environment
shows their relevant characteristics relative to the whole
sample, creating the basis for correct total and minor
allele copy number calls. This is especially useful when
tumor cell heterogeneity or normal cell content would
complicate the analysis.
The current state of tumor copy number analysis
A number of recent bioinformatic methods use allele-spe-
cific information to take aneuploidy or non-tumor cells
into account in detecting genomic aberrations. Due to
the different signal and noise characteristics of microarray
platforms, most methods are designed to work on array
data from one platform only. Some specialize on cell
lines, handling aneuploidy well on very pure cancer sam-
ples but without taking normal cell content into account
[8]. Recent methods that model the contributions from
aneuploidy and non-tumor cells at the same time are
GAP, ASCAT and PSCN [9,11,13]. These methods
require identification of individual informative SNP mar-
kers that are heterozygous in non-tumor cells, either
from the tumor sample data or from genotyping matched
non-tumor tissue samples on a separate array. TAPS uses
a clustering solution to estimate the relationship between
heterozygous and homozygous SNPs, and requires no
clear separation between them. GAP and ASCAT per-
form better than the previous generation of methods.
However, at least for some notoriously difficult types of
tumors such as breast cancer, a considerable fraction
(19%) of tumors does not fit the ASCAT models well
enough to be analyzed [11]. In addition, samples tend
not to fit these models beyond copy number 4 to 6
[9,11]. Reasons for limited performance may be that
some factors affecting the array intensities are
unknown, that certain copy number variants required
by the model are missing, and that tumor cell hetero-
geneity prevents the data from fitting the models. The
result is that many samples can either not be analyzed
or the prediction of allele-specific copy numbers will
be incorrect.
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Figure 1 Schematic illustration of the Tumor Aberration Prediction Suite (TAPS) method for visualization of chromosomal aberrations
in tumor samples. A scatter plot of the average Log-ratio and the allelic imbalance ratio of all segments in a sample reveals the aberrations
present. (a) The example chromosome is segmented with respect to Log-ratio and allele frequency. (b) In the allele frequency pattern, the
probes’ distance from heterozygosity (equal signal from alleles A and B) is clustered on two means, representing heterozygous (dhet) and
homozygous (dhom) SNPs. The allelic imbalance ratio dhet/dhom ranges from near zero with equal allelic copy numbers and low noise to near
one with loss-of-heterozygosity (LOH), low normal cell contamination and low noise. (c) Schematic illustration of a Log-ratio/allelic imbalance
ratio scatter plot. An example region in blue can be identified as cn2m0, that is, copy number 2 and minor copy number 0 (LOH). Each object in
the scatter plot corresponds to a chromosomal segment. Segments are colored according to their chromosomal position (a) and segments on
other chromosomes of the same sample are plotted in grey. The number of possible variants of allele-specific copy number increases with the
total copy number. Lower copy numbers are more affected by noise and normal cell contamination, which reduce any allelic imbalance.
Deletions and copy number neutral LOH may therefore show less allelic imbalance than high copy numbers that retain one or more copies of
its minor allele. Note how variants with the same minor copy number tend to line up diagonally, facilitating the interpretation.
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Page 3 of 10Performance on low tumor cell content
TAPS was compared to three other recently developed
tools for allele-specific copy number analysis of SNP6
a r r a y s :P I C N I C ,G A Pa n dP S C N[ 8 , 9 , 1 3 ] .T oe v a l u a t e
performance on samples with normal cell contamina-
tion, we prepared a dilution series by mixing DNA from
lung cancer cell line H1395 and its patient-matched
blood cell line BL1395 (with normal karyotype). Four
samples with normal cell proportions ranging from 30%
to 100% were analyzed on SNP6 arrays and the resulting
data subjected to copy number analysis with the four
methods. Overall sensitivity is shown in Figure 2a and
performance on regions with LOH is shown in Figure
2b. With high tumor content, aberrations with and
without LOH were well detected by TAPS and GAP.
PICNIC, which is designed for cell lines, proved excel-
lent at 100% tumor cells but vulnerable to normal cell
content. TAPS performed particularly well with a low
proportion of tumor cells, demonstrating high sensitivity
at 30% tumor cells. The performance of PSCN was simi-
lar except that it reported incorrect total copy number
(though finding LOH) of some aberrations with LOH at
high tumor cell content. All four methods showed
impressive specificity (Figure 2c). Note, however, that
PICNIC and GAP reported most or all of the genome as
unaltered at 30% tumor cells. Raw data and copy num-
ber output are available at the Gene Expression Omni-
bus (GEO) with accession number [GEO:GSE29172].
TAPS scatter plots visualizing copy numbers at different
tumor cell proportions are available in Additional file 1.
Chromosomal aberrations in lung cancer cell lines
To evaluate the performance of TAPS on samples with
varying ploidy, we retrieved published SKY karyotypes
and Affymetrix 250 K array data [GEO:GSE17247] for
seven lung cancer cell lines [17,18]. For each sample, we
performed segmentation of the genome with respect to
allele-specific intensities. We then visualized each seg-
ment relative to the full-sample background using
TAPS. Five samples were found to have an average copy
n u m b e ra b o v e2 . 5 .I na l ls e v e nw ew e r ea b l et ov a l i d a t e
the average ploidy with the SKY karyotypes. The SKY
karyotype of cell line H1395 reported two heterogeneous
aberrations where about 50% of the cells would carry
each variant. We cultured H1395 cells and analyzed
them on a SNP6 array to improve data quality and reso-
lution. We could clearly observe the expected tumor cell
heterogeneity for both loci, one with a mix of normal
ploidy and a specific aberration, and one with a mix of
two different aberrations (Figure 3a, b).
Variable copy numbers and double minutes
The automatic copy number analysis of TAPS does not
predict all copy number intensities from a single mathe-
matical model. Instead the intensities observed for lower
copy numbers are used iteratively to predict those of
higher copy numbers. On short aberrations, noise may
cause segmentation errors, making the exact copy num-
ber hard to determine. This is of particular importance
for genomic aberrations such as double minutes (DMs),
as their numbers vary greatly between cells and the
observed copy number reflects an average [14]. To this
end, TAPS copy number analysis outputs an additional
set of short-segment scatter plots, where the segments
produced by circular binary segmentation (CBS) have
been further segmented into regions of 200 to 400 mar-
kers. On such a plot of chromosome 11 from H1395, a
region on the q arm displays several short copy number
aberrations afflicting only one of the original sister chro-
mosomes (Figure 4). SKY karyotyping of the cell line has
previously identified DMs from chromosome 11 [18].
This region is further illustrated at different tumor cell
concentrations in Additional file 1. The allelic imbalance
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Figure 2 Performance of TAPS and three other methods in identifying aberrations influenced by normal cell content. The performace
of TAPS is compared to three other methods, PICNIC, PSCN and GAP. (a) Sensitivity as the percentage of correctly identified out of 35 large
aberrations. (b) Sensitivity in the subset of (a) with loss of heterozygosity (n = 14). (c) Specificity as the percentage of unaltered genome that
was correctly reported as unaltered. All methods showed high specificity, partially due to some of them reporting everything as unchanged at
low tumor cell content.
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Page 4 of 10ratio remains sensitive to small differences in allele fre-
quency for very short segments, and TAPS is therefore
suitable for investigating this particular form of tumor
heterogeneity.
A key to a thorough analysis with TAPS is the visuali-
zation of samples, which allows the researcher to assess
widespread tumor heterogeneity, average ploidy and
normal cell content. This visual inspection allows the
researcher to identify samples that may be problematic
due to frequent tumor cell heterogeneity, very low
tumor cell content or poor quality. Such samples can
usually be handled by the automatic copy number analy-
sis, but some manual input may be required.
Chromosomal aberrations in colorectal cancer tumor
samples
Twelve colorectal cancer tissue samples analyzed on
Affymetrix SNP 6.0 arrays were used to evaluate the
performance of TAPS on tumor samples. Allele-specific
copy numbers were produced using TAPS automated
calling. Four samples, two with predicted aneuploidy,
were selected for DNA ploidy analysis (see Materials
and methods) as an independent measure of the average
ploidy of the tumor cells. Total copy numbers and
LOH, and computed and independently measured aver-
age ploidy for all 12 samples are shown in Figure 5. The
high correspondence between the average copy number
in the tumor cells obtained by TAPS and DNA ploidy
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Figure 3 Identification of heterogeneity within the tumor cell population. Plotting a chromosome highlighted against the whole sample
allows discovery of genomic regions with heterogeneity within the tumor cell population, shown here on two regions in lung cancer cell line
H1395. The arrows mark the chromosomal segments and their respective positions in the scatter plots. (a) On chromosome 1, most of the q
arm has loss of heterozygosity and an average of about 3.5 copies. The high-copy segment near the centromere is not visible in this scatter plot.
(b) The end of 10q is seen between the clusters for normal ploidy and deletion, indicating deletion only in part of the cell population.
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Figure 4 Double minute chromosomes in a lung cancer cell
line. A short-segment TAPS scatter plot illustrates the origin of
double minute chromosomes (DMs). Lung cancer cell line H1395
has three copies of chromosome arm 11p (blue) and no loss of
heterozygosity (LOH). Most of 11q is copy number 2 with LOH (red).
The DMs appear as several successive short segments with varying
total copy numbers (violet). Their minor allele varies between zero
and two copies when the major allele has two copies, and remains
at two when the major allele is above two. This suggests that
circular DMs originate from the sister chromosome that in most of
11q has been lost. The remaining sister chromosome is duplicated
but otherwise unchanged.
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Page 5 of 10analysis indicates that TAPS is highly suitable for ana-
lyzing tumor samples.
Limitations
TAPS has been developed and validated for SNP array
data from Affymetrix 500 K and SNP 6.0 arrays. As long
as allele-specific signals are not subjected to processing
meant only for genotyping of diploid samples, we expect
the TAPS approach to work well on data from other
platforms. With the different noise characteristics and
data processing of non-Affymetrix microarrays, auto-
matic copy number calling with TAPS should not be
expected to work without modification.
Before copy number analysis in TAPS, raw intensity
data should be normalized and segmented. We found a
wide selection of tools (including Affymetrix Power
Tools, AROMA and Biodiscovery/Nexus Copy Number)
to perform satisfactory normalization and can thus be
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Figure 5 Allele-specific copy number aberrations and ploidy in 12 colon cancer samples. Genome-wide overview of copy numbers (CN)
determined by TAPS are indicated using color (see key in figure). In addition, loss of heterozygosity (LOH) is indicated using thin lines. Note the
extensive presence of LOH in many samples, often coinciding with high copy numbers. Average ploidy of tumor cells calculated using TAPS and
through DNA ploidy analysis.
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Page 6 of 10used with TAPS. For direct use of .CEL files a wrapper
that uses AROMA CRMAv2 [19] to process raw intensi-
ties is available with TAPS. Segmentation is normally
performed either with a hidden Markov model (HMM)
or with CBS, the latter of which is available in R
through the DNACopy package as well as in Nexus and
other software. While a HMM is generally capable of
producing fewer incorrect segment breaks than CBS, it
requires a very good prior estimate of the signal-copy
number relationship to do so. Moreover, tumor cell het-
erogeneities frequently manifest as non-integer copy
numbers, causing a HMM segmentation to oscillate
almost randomly between the nearest integer copy num-
bers. We found the CBS segmentation approach to be
much more suitable for tumor data, and recommend it
for use with TAPS.
Molecular methods that analyze extracts from tumor
tissue have general limitations. One problem is that the
heterogeneity of tumor cells has the consequence that
unless the entire tumor is used for the molecular analy-
sis, there will be a sampling of the tumor cells. The
extracted DNA will thus be more or less representative
of the tumor cells of the tumor.
In the colon cancer material, DNA was extracted from
sections of the tumor tissue, achieving a reasonable,
albeit not perfect, representation of the tumor. Thus,
additional genomic aberrations may therefore be present
in the tumor cells that may be missed due to insuffi-
cient sampling. However, since relatively little tumor
cell heterogeneity is detected in the material that was
sampled, we believe that genomic aberrations present in
a major proportion of the tumor cells rarely remain
undetected.
Improved bioinformatic tools are important for analy-
sis of tumor samples on SNP microarrays. Conse-
quences of poor performance of such tools include
systematically underestimating copy numbers in hyper-
ploid tumors, false detection of LOH where the minor
copy number is relatively low, and failure to detect aber-
rations at all due to the presence of normal cells that
weaken the signal from tumor cells. Improved data ana-
lysis may become a decisive factor that improves the
overall analysis to allow the discovery of significantly
new genomic factors with important roles in tumor
development.
A new generation of large-scale DNA sequencing
technologies is starting to be applied to tumor samples
[15,20,21]. It should be pointed out that the issues rele-
vant for analyzing tumors using SNP microarrays are
equally relevant for sequencing technologies. Methods
such as TAPS need to be developed for sequencing data
and will allow correct identification of genomic aberra-
tions in tumor samples analyzed by sequencing.
Conclusions
TAPS provides reliable information on allele-specific
copy number in tumor samples analyzed on Affymetrix
arrays, without the need for matched normal samples.
The use of TAPS may help in elucidating critical events
in tumor development that could affect care and man-
agement of cancer patients.
Materials and methods
Allelic imbalance ratio
TAPS uses the B-allele frequencies (BAF), defined as (B/
(A + B)), where A and B are the normalized intensities
of the A and B probes, to calculate the allelic imbalance
ratio of genomic segments. TAPS takes the absolute
values of BAF - 0.5 (the distance to equal A and B sig-
nal, for each SNP) and clusters on two means, repre-
senting heterozygous and homozygous SNPs. The allelic
imbalance ratio is produced by dividing the inner cluster
center by the outer. The resulting value will be close to
zero in cases of a balanced copy number variant (usually
about 0.1 due to forcing two means, and the effects of
noise), and similarly close to one in cases of a very
unbalanced copy number variant (such as a high copy
number with LOH) and very low normal cell content.
Copy number visualization
For each segment, TAPS considers the mean Log-ratio
of all probes and the allelic imbalance ratio of the SNPs.
The mean Log-ratio reflects the total copy number of
the segment. The allelic imbalance ratio reflects the
relationship between the alleles. However, with an
unknown average ploidy of tumor cells and an unknown
proportion of normal cells, the exact relationship
between Log-ratio, allelic imbalance ratio and the allele-
specific copy numbers of the tumor cells will vary
between samples.
To visualize the tumor aberrations in a sample, Log-
ratio is plotted against allelic imbalance ratio for all seg-
ments. A high proportion of normal cells reduces the
allelic imbalance caused by imbalanced tumor aberra-
tions, and the effect on Log-ratio of total copy number
changes. However, segments will still appear in a pre-
dictable fashion with respect to one another, and a good
assessment can be made with as little as 30% tumor
cells (Figure 3).
Copy number calling
TAPS includes an algorithm for automatic estimation of
total and minor copy number. It first estimates the
(sample-specific) relationship between Log-ratio, allelic
imbalance and copy numbers. This crucial step can be
assisted by a visual interpretation of the TAPS scatter
plots. The calling algorithm implemented in TAPS then
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Page 7 of 10uses the Log-ratio and allelic imbalance ratio of lower
copy numbers to estimate the characteristics of higher
copy numbers. By iteratively working from lower to
higher copy numbers, TAPS continuously adjusts expec-
tations according to observations. TAPS is available
from the authors as extensively commented R code. A
simplified overview is presented here.
Step 1: estimate the Log-ratio of copy number two,
using the Log-ratio and allelic imbalance ratio of the
lowest-intensity long autosomal segments. The relatively
low allelic imbalance of unaltered regions compared to
LOH and single-copy gains and losses is the best indica-
tor of copy number 2.
Step 2: find the allelic imbalance ratio of cn1, cn2m1
(2 with minor copy number 1) and cn2m0 (2 with
minor copy number 0, that is, LOH) from all segments
belonging to copy numbers 1 and 2.
Step 3: if step 1 or 2 fails, the analyst may supply an
initial interpretation from a TAPS scatter plot.
Step 4: for each successive higher copy number, use
the difference in Log-ratio between lower copy numbers
to estimate its Log-ratio. Set it to the median of any seg-
ments that match the expectation well (note that seg-
ments are weighted on their length). If no such
segments exist, set it to the expectation. The Log-ratio
difference between successively higher copy numbers
tends to drop slowly but steadily, and this way TAPS
adjusts its expectations according to observations in the
current sample.
Step 5: at copy number 3 and higher, use the differ-
ences in allelic imbalance ratio seen on lower copy
number variants (such as cn1, cn2m1 and cn2m0 for
copy number 3) to predict the allelic imbalance ratio of
copy number variants (such as cn3m1 and cn3m0). Set
them to the median of any segments of the correct copy
number that closely match the expectation (note that
segments are weighted on their length). If no such seg-
ments exist, set it to the expectation. This step uses the
tendency of copy number variants with the same minor
copy number to line up diagonally (with a slowly
decreasing slope), which can be seen in the TAPS scat-
ter plots.
Sample preparation and microarray experiments
Twelve colon cancer samples were selected from a set of
immediately frozen tumor biopsies from patients oper-
ated upon for a colorectal cancer at the hospitals in
Uppsala or Västerås, Sweden. Two of the 12 had
appeared to fit a conventional copy number analysis
well, while the remaining 10 had raised suspicions of
hyperploidy. All patients gave informed consent accord-
ing to the research ethical committee at Uppsala Uni-
v e r s i t yf o rt h es t o r a g e ,i s o l a t i o no fD N Aa n du s eo ft h e
material in research projects. The tumor cell content in
each sample was at least 50% based upon an examina-
tion by a pathologist (JB or PM) of a hematoxylin-eosin
stained section. All patients had stage II and III colon
cancer. All samples were fully anonymized. DNA was
extracted from two to ten frozen tissue sections (10 μm)
using the QIAamp DNA Mini Kit (Qiagen, Hilden, Ger-
many). DNA concentrations were measured with a ND-
1000 spectrophotometer (NanoDrop Technologies, Wil-
mington, DE, USA).
Lung cancer cell line H1395 and patient-matched
blood cell line BL1395 were obtained from the Ameri-
can Type Culture Collection (ATCC) and cultured
according to their recommendations. DNA extraction
was performed using the DNeasy Tissue Kit (Qiagen).
Dilutions representing 30, 50 and 70% tumor cell con-
tent were prepared from the extracted DNA. The higher
(near-triploid) DNA content of the tumor cells was
compensated for by using 42, 65 and 80% tumor DNA.
Array experiments were performed according to the
standard protocols for Affymetrix Genome-Wide
Human SNP Array 6.0 arrays (Cytogenetics Copy Num-
ber Assay User Guide, P/N 702607 Rev2), Affymetrix
Inc., Santa Clara, CA, USA). Quality control was per-
formed in Affymetrix Genotyping Console version 3.0.
Array data, including the cell line and colorectal tumor
copy numbers, are available at the GEO [GEO:
GSE26302].
Data preparation and analysis
Raw data (.CEL files) from colorectal cancer samples
were normalized, Log-ratio and allele frequency was
extracted and segmentation was performed in BioDis-
covery Nexus Copy Number 3.0 with European HapMap
samples as a reference set and using the Rank Segmen-
tation algorithm based on CBS. Downstream analysis
was performed in R using the TAPS suite, including
allelic imbalance ratio calculation, plotting and copy
number calling.
Published lung cancer cell line raw data (Affymetrix
GeneChip Human Mapping 250 K) were processed in
BioDiscovery Nexus Copy Number 3.0 with European
HapMap samples as a reference set and using the Rank
Segmentation algorithm. Downstream analysis of Log-
ratio, allele frequency and segments was performed in R
using the TAPS suite. The average copy number of each
sample was read from the TAPS scatter plots. SKY kar-
yotypes from samples H2122, H2126, H1395, H1437,
H1770, H2087 and H2009 were downloaded and used
to verify the result of TAPS [18]. Summaries of the ana-
lysis are available in Additional file 2.
Comparative analysis
Copy number analysis with PICNIC, GAP, PSCN and
TAPS was performed on SNP6 raw data from the three
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Page 8 of 10diluted samples (30, 50 and 70% tumor cells) and the
pure H1395 cell line. We selected all aberrations on
which the allele-specific copy number calls of at least
three of the four methods coincided for the all-tumor-
cell sample. These were 35 large regions, representative
of all types of copy number aberrations in the sample,
and covered the majority of the genome. We then
observed whether the four methods, for each region,
gave matching copy number calls in the normal cell-
diluted samples. Sensitivity was calculated as percentage
of the 35 aberrations that were mostly correct (correct
allele-specific copy numberi nm o r et h a nh a l fo ft h a t
region). Since different segmentation strategies are used
by the different methods, exact breakpoints were not
considered important. Specificity was measured by first
defining the truly unaltered genome using the pure
tumor sample and concurring (heterozygous copy num-
ber 2) calls of at least three methods. We then summed
up, for the four methods and the diluted samples, the
percentage of the truly unaltered genome (True nega-
tives + False positives) that were reported as such (True
negatives), applying the general definition of specificity
as True negatives/(True negatives + False positives).
Automatic copy number analysis was used with all
methods.
DNA ploidy analysis
Formalin-fixated, paraffin-embedded tissues correspond-
ing to four of the colorectal cancer tissue samples were
deparaffinized and analyzed for DNA content as pre-
viously described [22].
Additional material
Additional file 1: Dilution series summary. This file illustrates the
sensitivity of TAPS using short-segment scatter plots of lung cancer cell
line H1395, for several different tumor cell concentrations.
Additional file 2: Lung cancer cell line summaries. This file contains
TAPS scatter plots illustrating the copy number analysis result of the
seven lung cancer cell lines, and matching SKY karyotypes for
comparison.
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